David A. Wood, MD; Janarthanan Sathananthan, MBChB, MPH
Transcatheter aortic valve implantation (TAVI) may become the predominant therapy for the majority of patients with calcific aortic stenosis, irrespective of surgical risk1,2. This reflects an expansion in indications over time since the initial cases were performed over 15 years ago. Similarly, implantation technique and preprocedural, periprocedural and post-procedure care have evolved with many centres adopting a “minimalist” approach for TAVI cases.
In this issue of EuroIntervention, Costa and colleagues demonstrate the safety and efficacy of next-day discharge in a large series of unselected patients at a single centre3.
After adjustment, there were no differences in ...